Lymphoma, T-Cell - 77 Studies Found
Recruiting |
: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma :
|
Terminated |
: CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma : T-cell Lymphoma : 2009-05-05 :
|
Not yet recruiting |
: Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients : Peripheral T Cell Lymphoma : 2016-11-03 :
|
Recruiting |
: Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study : Peripheral T-cell Lymphomas : 2015-07-26 :
|
Recruiting |
: Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma : Cutaneous T Cell Lymphoma : 2010-05-25 : Drug: Lenalidomide Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated |
Completed |
: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) : Lymphoma, T-Cell, Cutaneous : 2011-09-09 :
|
Completed |
: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma : Lymphoma, T-Cell, Cutaneous : 2011-11-29 : Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma : Lymphoma, T-Cell, Cutaneous : 2002-08-08 :
|
Completed |
: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) : Lymphoma, T-Cell, Cutaneous : 2005-09-13 : Drug: ONTAK (denileukin difitox, DAB389IL-2) |
No longer available |
: Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) : Lymphoma, T-Cell, Cutaneous : 2007-01-05 : Drug: Comparator: vorinostat Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treat |